Showing results (191-200 of 243) with videos related to

Sort By:
Pageof 25
Cancers|June 19, 2024
Radiotherapy Plan Quality Assurance in NRG Oncology Trials for Brain and Head/Neck Cancers: An AI-Enhanced Knowledge-Based ApproachDu Wang, Huaizhi Geng, Vinai Gondi, et al.
The Journal of Clinical Investigation|December 25, 2010
Systemic combinatorial peptide selection yields a non-canonical iron-mimicry mechanism for targeting tumors in a mouse model of human glioblastomaFernanda I Staquicini, Michael G Ozawa, Catherine A Moya, et al.
Neuro-Oncology|February 13, 2021
Ultra high-risk PFA ependymoma is characterized by loss of chromosome 6qLorena V Baroni, Lakshmikirupa Sundaresan, Ayala Heled, et al.
Neuro-Oncology|July 18, 2020
CODEL: phase III study of RT, RT + TMZ, or TMZ for newly diagnosed 1p/19q codeleted oligodendroglioma. Analysis from the initial study designKurt A Jaeckle, Karla V Ballman, Martin van den Bent, et al.
Clinical Chemistry|January 29, 2015
Clinical actionability enhanced through deep targeted sequencing of solid tumorsKen Chen, Funda Meric-Bernstam, Hao Zhao, et al.
Frontiers in Immunology|May 15, 2025
Dedifferentiated liposarcomas treated with immune checkpoint blockade: the MD Anderson experienceMadeline B Torres, Cheuk Hong Leung, Marianne Zoghbi, et al.
The New England Journal of Medicine|February 21, 2014
A randomized trial of bevacizumab for newly diagnosed glioblastomaMark R Gilbert, James J Dignam, Terri S Armstrong, et al.
JCO Precision Oncology|September 30, 2021
Long-Term Report of a Comprehensive Molecular and Genomic Analysis in NRG Oncology/RTOG 0424: A Phase II Study of Radiation and Temozolomide in High-Risk Grade II GliomaJessica L Fleming, Stephanie L Pugh, Barbara J Fisher, et al.
The New England Journal of Medicine|December 24, 2010
NFKBIA deletion in glioblastomasMarkus Bredel, Denise M Scholtens, Ajay K Yadav, et al.
JAMA Oncology|June 30, 2018
Association of MGMT Promoter Methylation Status With Survival Outcomes in Patients With High-Risk Glioma Treated With Radiotherapy and Temozolomide: An Analysis From the NRG Oncology/RTOG 0424 TrialErica H Bell, Peixin Zhang, Barbara J Fisher, et al.
Pageof 25